

To,

Date: 13.11.2025

BSE Limited

P. J. Towers,
Dalal Street,
Mumbai – 400001

Unit: Decipher Labs Limited (Scrip Code: 524752)

Sub: Outcome of Board Meeting held on Thursday, 13th November, 2025.

Dear Sir/ Madam,

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Decipher Labs Limited** at its meeting held on Thursday, the 13th day of November, 2025 at 05:30 P.M. at registered office of the Company considered and approved the following:

1. Un-audited Financial Results (Standalone and Consolidated) for the Quarter and half year ended 30th September 2025. (**Attached**).
2. Limited Review Report (Standalone and Consolidated) for the Quarter and half year ended 30th September 2025. (**Attached**).
3. Appointment of Mr. Dalavath Amar Singh (DIN - 02206249) as an Additional Director (Executive Category) of the Company for a period of Two (2) years w.e.f. 13.11.2025, subject to approval of members in the ensuing General Meeting. (Details are annexed as **Attached A**).

The meeting concluded at 06:40 P.M.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Faithfully

For Decipher Labs Limited

Sushant Mohan Lal

Non-Executive Director

(DIN- 01227151)

Encl. as above

Annexure A

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A, Point 7 of Annexure 18 of Chapter V Section V-A of SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024]

Appointment of Mr. Amar Singh Mathur as Additional Director (Executive Category) of Decipher Labs Limited

Particulars	Mr. Dalavath Amar Singh
Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of Mr. Dalavath Amar Singh as an Additional Director (Executive Category) of Decipher Labs Limited.
Date of appointment & Terms of appointment	Date of Appointment: 13.11.2025 Terms of Appointment: Appointed for the period of Two (2) year(s) at a remuneration of Rs. 6,00,000/- (Rupees Six Lakhs Only) per annum subject to the approval of shareholders.
Brief Profile	Mr. Dalavath Amarsingh possesses operational experience in the pharmaceutical industry. With an understanding of plant operations, team coordination, and production processes, he brings valuable on-ground insight to the Board.
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no NSE/CML/2018/24 dated June 20, 2018	Mr. Amar Singh is not debarred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.

DECIPHER LABS LIMITED
(CIN L24230TG1986PLC006781)
Regd.off: A-2, Q2, 5th Floor, Cyber Towers
Madhapur, Hyderabad, Telangana, India - 500081
URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040 29323151
Standalone statement of Assets and Liabilities as on 30th September, 2025

Rs. in Lakhs

Particulars	As at 30th Sep 2025	As at 31st March 2025
	Unaudited	Audited
I. ASSETS		
Non-current assets		
(a) Property Plant and Equipment	12.89	13.80
(b) Financial assets		
Investments	866.41	866.41
(c) Other non-current assets	3.50	3.50
(d) Deferred Tax Assets	1.36	1.68
Current assets		
(a) Financial assets		
(i) Trade receivables	45.67	22.68
(ii) Cash and cash equivalents	4.80	5.47
(b) Current tax assets	0.21	0.21
(c) Other current assets	14.92	4.08
TOTAL ASSETS	949.76	917.82
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,010.00	1,010.00
(b) Other equity	(167.23)	(161.27)
Liabilities		
Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	42.56	24.45
(ii) Trade payables		
a) Total outstanding dues of Micro and small enterprises	-	-
b) Total outstanding dues of creditors other than Micro and small enterprises	41.24	23.78
(iii) Other financial liabilities	21.69	20.05
(b) Other current liabilities	1.50	0.81
TOTAL EQUITY AND LIABILITIES	949.76	917.82

For and on behalf of the Board



Susnant Monan Lai
Director
DIN: 01227151

Place: Hyderabad
Date: 13.11.2025

DECIPHER LABS LIMITED

(CIN L24230TG1986PLC006781)

Regd.off: A-2, Q2, 5th Floor, Cyber Towers

Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040 29323151

Statement of Unaudited Standalone Financial Results For the Quarter ad Half Year Ended 30th September, 2025

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Half Year Ended		Year ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	8.80	84.65	8.38	93.45	46.72	85.32
II. Other income	0.02	-	1.77	0.02	1.94	2.28
III. Total Income (I + II)	8.83	84.65	10.15	93.48	48.66	87.60
IV. Expenses						
Purchase of Stock in trade	(0.00)	64.10	-	64.10	29.25	67.25
Changes in inventories of stock in trade	-	-	-	-	-	-
Employee Benefits Expense	3.85	3.85	4.40	7.70	12.12	23.43
Finance Costs	-	-	-	-	-	-
Depreciation expense	0.45	0.45	0.45	0.90	0.77	1.67
Other expenses	16.20	10.22	11.05	26.42	24.88	39.14
Total expenses	20.50	78.62	15.89	99.12	67.01	131.49
V. Profit/(Loss) before Exceptional items (III - IV)	(11.67)	6.03	(5.74)	(5.64)	(18.34)	(43.90)
VI. Exceptional items	-	-	-	-	-	-
VII. Profit/(Loss) after Exceptional items (V - VI)	(11.67)	6.03	(5.74)	(5.64)	(18.34)	(43.90)
VIII. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	(0.12)	0.44	(0.11)	0.32	0.36	(0.13)
IX. Profit/(Loss) for the period (VII-VIII)	(11.55)	5.59	(5.63)	(5.96)	(18.70)	(44.02)
X. Other comprehensive income	-	-	-	-	-	-
XI. Total comprehensive income for the year	(11.55)	5.59	(5.63)	(5.96)	(18.70)	(44.02)
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
XII. Earning per equity share						
(1) Basic	(0.11)	0.06	(0.06)	(0.06)	(0.19)	(0.44)
(2) Diluted	(0.11)	0.06	(0.06)	(0.06)	(0.19)	(0.44)

Notes

1. The operations of the Company relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Half Year Ended		Year Ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharmaceutical drugs	-	67.50	-	67.50	30.00	68.60
b) Consultancy Services	8.80	17.15	8.38	25.95	16.72	16.72
Total Sales	8.80	84.65	8.38	93.45	46.72	85.32
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	8.80	84.65	8.38	93.45	46.72	85.32
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharmaceutical drugs	(8.88)	4.81	(1.92)	(4.07)	(11.79)	(35.29)
b) Consultancy Services	(2.79)	1.22	(3.83)	(1.57)	(6.57)	(8.60)
Total	(11.67)	6.03	(5.74)	(5.64)	(18.35)	(43.90)
Less: Interest and exceptional items	-	-	-	-	-	-
Total Profit before tax	(11.67)	6.03	(5.74)	(5.64)	(18.35)	(43.90)
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	949.58	999.00	893.52	949.58	893.52	913.55
b) Consultancy Services	0.18	4.28	16.73	0.18	16.73	4.27
Total Assets	949.76	1,003.28	910.25	949.76	910.25	917.82
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	106.99	148.96	20.30	106.99	20.30	69.09
b) Consultancy Services	-	-	-	-	-	-
c) Unallocated liabilities	-	-	-	-	-	-
Total Liabilities	106.99	148.96	20.30	106.99	20.30	69.09

2. The above results for the quarter and half year ended 30th September 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13th November 2025.

3. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151

Place: Hyderabad
Date: 13.11.2025

DECIPHER LABS LIMITED (CIN L24230TG1986PLC006781) Regd.off: A-2, Q2, 5th Floor, Cyber Towers Madhapur, Hyderabad, Telangana, India - 500081 URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040 29323151 Standalone Statement of Cash Flows for the Half Year Ended 30th September 2025 All amounts in ₹ Lakhs, unless otherwise stated				
Particulars	Half Year ended 30th September, 2025 (Unaudited)		Year ended 31st March, 2025 (Audited)	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		(5.64)		(43.90)
Adjustments for :				
Depreciation		0.90		1.67
Loss on sale of asset		-		(0.37)
Operating Profit before Working Capital Changes		(4.74)		(42.60)
Adjustments for:				
(Increase) / Decrease in Trade Receivables	(22.99)		371.82	
(Increase) / Decrease in Other Assets	(10.84)		(4.29)	
(Increase) / Decrease in Other Non Current Assets	-		(3.20)	
Increase / (Decrease) in Trade Payable	17.47		(345.86)	
Increase / (Decrease) in Other Liabilities	20.44		31.61	
		4.08		50.08
Cash Generated from Operations		(0.67)		7.48
Direct Taxes Paid		-		-
Net Cash generated from/(used in) Operating Activities		(0.67)		7.48
B. CASH FLOW FROM INVESTING ACTIVITIES				
Sale of Fixed Asset	-		1.02	
Purchase of Fixed Asset	-		(5.69)	
Net Cash used in Investing Activities		-		(4.67)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Net decrease in Cash and Cash Equivalents		(0.67)		2.82
Cash and Cash Equivalents at the beginning of the year		5.47		2.65
Cash and Cash Equivalents at the end of the period		4.80		5.47



Place: Hyderabad
Date: 13.11.2025

For and on behalf of the Board

Sushant Mohan Lal
Director
DIN: 01227151

Decipher Labs Limited
(CIN L24230TG1986PLC006781)
Regd.off: A-2, Q2, 5th Floor, Cyber Towers
Madhapur, Hyderabad, Telangana, India - 500081
URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040 29323151
Consolidated Statement of Assets and Liabilities as on 30th September, 2025
All amounts in ₹ Lakhs, unless otherwise stated

Particulars	As at 30th September, 2025 (Unaudited)	As at 31st March, 2025 (Audited)
I. ASSETS		
Non-current Assets		
(a) Property, Plant and Equipment	81.11	82.83
(b) Investment	26.41	26.41
(c) Deferred tax asset (net)	194.48	187.52
(d) Goodwill	159.26	171.19
(e) Other non current assets	3.50	3.50
Current Assets		
(a) Financial assets		
(i) Trade receivables	325.74	421.63
(ii) Cash and cash equivalents	80.07	280.84
(iii) Other Financial Asset	159.88	201.64
(b) Other current assets	1,345.57	1,200.91
TOTAL ASSETS	2,376.02	2,576.48
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,010.00	1,010.00
(b) Other equity	904.28	1,275.57
Liabilities		
Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	42.56	24.45
(ii) Trade payables		
a) Total outstanding dues of Micro enterprises and small enterprises	-	-
b) Total outstanding dues of creditors other than Micro enterprises and small enterprises	166.30	115.67
(iii) Other Financial liabilities	251.38	149.98
(b) Other current liabilities	1.50	0.81
TOTAL EQUITY AND LIABILITIES	2,376.02	2,576.48

For and on behalf of the Board



Place: Hyderabad
Date: 13.11.2025

Sushant Mohan Lal
Director
DIN: 01227151

Decipher Labs Limited
(CIN L24230TG1986PLC006781)

Regd.off: A-2, Q2, 5th Floor, Cyber Towers
Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040 29323151

Statement of Audited Consolidated Financial Results For the Quarter and Half Year Ended September 30th, 2025

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31st March, 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	431.37	292.37	586.67	723.74	1,330.77	2,261.25
II. Other income	2.05	1.12	12.09	3.17	27.90	131.82
III. Total revenue (I + II)	433.42	293.49	598.76	726.91	1,358.67	2,393.07
IV. Expenses						
Purchase of Stock-in-Trade	-	64.10	-	64.10	29.25	67.25
Employee benefits expense	404.73	472.61	668.72	877.34	1,180.07	2,139.16
Finance costs	-	-	-	-	-	-
Depreciation and amortisation expense	12.54	11.71	11.50	24.25	22.78	47.63
Other expenses	14.26	87.30	51.28	101.56	123.52	777.65
Total expenses	431.53	635.72	731.50	1,067.25	1,355.62	3,031.69
V. Profit/(Loss) before Exceptional item (III - IV)	1.89	(342.23)	(132.74)	(340.34)	3.05	(638.62)
VI. Exceptional items	-	-	-	-	-	-
VII. Profit/(Loss) before tax (III - IV)	1.89	(342.23)	(132.74)	(340.34)	3.05	(638.62)
VIII. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	(0.12)	0.44	0.06	0.32	41.19	(130.60)
IX. Profit/(Loss) for the period (V-VI)	2.01	(342.67)	(132.80)	(340.66)	(38.14)	(508.02)
X. Other comprehensive income						
Items that will be reclassified to statement of profit and loss	-	-	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	(59.08)	28.45	28.26	(30.63)	28.02	52.38
XI. Total comprehensive income for the year	(57.07)	(314.22)	(104.54)	(371.29)	(10.12)	(455.64)
Net Profit/(Loss) for the year attributable to:						
Owners of the parent	2.01	(342.67)	(132.80)	(340.66)	(38.14)	(508.02)
Non-Controlling Interests	-	-	-	-	-	-
Other Comprehensive Income attributable to:						
Owners of the parent	(59.08)	28.45	28.26	(30.63)	28.02	52.38
Non-Controlling Interests	-	-	-	-	-	-
Total Comprehensive Income attributable to:						
Owners of the parent	(57.07)	(314.22)	(104.54)	(371.29)	(10.12)	(455.64)
Non-Controlling Interests	-	-	-	-	-	-
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
Director						
(1) Basic	0.02	(3.39)	(1.31)	(3.37)	(0.38)	(5.03)
(2) Diluted	0.02	(3.39)	(1.31)	(3.37)	(0.38)	(5.03)

Notes

1. The operations of the Group relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31st March, 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharmaceutical drugs	-	67.50	-	67.50	30.00	68.60
b) Consultancy Services	431.37	224.87	586.67	656.24	1,300.77	2,192.65
Total Sales	431.37	292.37	586.67	723.74	1,330.77	2,261.25
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	431.37	292.37	586.67	723.74	1,330.77	2,261.25
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharmaceutical drugs	(24.93)	4.80	(17.35)	(20.13)	(11.88)	(19.37)
b) Consultancy Services	26.82	(347.03)	(115.40)	(320.21)	14.92	(619.24)
Total	1.89	(342.23)	(132.74)	(340.34)	3.05	(638.62)
Less: Interest and exceptional item	-	-	-	-	-	-

Total Profit/(Loss) before tax	1.89	(342.23)	(132.74)	(340.34)	3.05	(638.62)
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	949.58	999.00	55.40	949.58	55.40	913.55
b) Consultancy Services	1,426.44	1,370.72	3,001.36	1,426.44	3,001.36	1,662.93
Total Assets	2,376.02	2,369.72	3,056.76	2,376.02	3,056.76	2,576.48
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	106.99	148.96	21.43	106.99	21.43	69.09
b) Consultancy Services	354.75	346.53	882.72	354.75	882.72	221.82
Total Liabilities	461.74	495.49	904.15	461.74	904.15	290.91

2. The above results for the quarter and half year ended 30th September 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13th November 2025.

3. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. The above results as of 30th September 2025 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA and step down subsidiary Decipher W.L.L., Bahrain.

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151

Place: Hyderabad
Date: 13.11.2025

Decipher Labs Limited

(CIN L24230TG1986PLC006781)

Regd.off: A-2, Q2, 5th Floor, Cyber Towers

Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040 29323151

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Half Year Ended 30th September, 2025 (unaudited)	Year Ended 31st March, 2025 (Audited)
Cash flow from operating activities		
Profit/(Loss) before tax	(340.34)	(638.62)
Adjustments for :		
Exchange differences on translating the financial statements of a foreign operation	(37.91)	52.38
Depreciation and amortisation expense	13.65	36.61
Finance costs	-	-
Baddebts written off	22.21	28.54
ERC Credit	-	555.14
Operating Profit before Working Capital Changes		
Changes in operating assets and liabilities		
(Increase) / Decrease in Trade Receivables	73.69	329.67
(Increase) / Decrease in Other Assets	(102.90)	(439.16)
Increase / (Decrease) in Trade Payable	50.63	(383.71)
Increase / (Decrease) in Other Liabilities	102.09	(522.68)
Cash Generated from Operations	(218.87)	(981.83)
Income taxes paid	-	-
Net cash inflow (outflow) from operating activities	(218.87)	(981.83)
Cash flows from investing activities		
Purchase of Fixed assets including Capital WIP	-	(5.69)
Impairment of investment/sale of investment	-	312.52
Net cash inflow (outflow) from investing activities	-	306.83
Cash flow from financing activities		
Proceeds/(repayment) of borrowings	18.11	24.45
Finance costs	-	-
Net cash inflow (outflow) from financing activities	18.11	24.45
Net increase (Decrease) in cash and cash equivalents	(200.76)	(650.54)
Cash and Cash equivalents at the beginning of the Year	280.84	931.38
Cash and Cash equivalents at the end of the Year	80.07	280.84



Director

Place: Hyderabad

Date: 13.11.2025

For and on behalf of the Board

Sushant Mohan Lal

DIN: 01227151



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Decipher labs Limited (Formerly known as Combat Drugs Limited) (the "Company") for the quarter ended 30th September, 2025 and year to date results for the period 1st April, 2025 to 30th September, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)

K.Sreenivasan
Partner
Membership No.206421

UDIN: 25206421BMIWJA3065
Place : Secunderabad
Date : 13.11.2025





Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited (Formerly known as Combat Drugs Limited)


1. We have reviewed the accompanying Statement of unaudited consolidated financial Results of Decipher labs Limited (Formerly known as Combat Drugs Limited) ("the Holding Company") and its subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 30th September, 2025 and year to date results for the period 1st April, 2025 to 30th September, 2025 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated 11th July, 2023 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable
4. The Statement includes the results of the subsidiary Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain.



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiaries referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain included in the consolidated unaudited financial results whose interim financial results reflect total assets of of Rs. 2194.28Lakhs as at 30th September 2025, total revenues of Rs 422.57lakhs and Rs. 630.29 lakhs, total net profit after tax of Rs13.56 lakhs and Rs. (334.70) lakhs, total comprehensive Income of Rs.(45.52) lakhs and Rs. (365.33) lakhs for the quarter ended 30th September, 2025 and for the period from 1st April, 2025 to 30th September, 2025 respectively and net cash outflows of Rs.200.09 Lakhs for the period from 1st April, 2025 to 30th September 2025 as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of these subsidiaries is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)


K.Sreenivasan

Partner
Membership No.206421

UDIN: 25206421BMIWJB2684

Place : Secunderabad

Date : 13.11.2025

